OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease
Clinical trial NCT03487666 · COMPLETED
Trial details
- NCT number
- NCT03487666
- Sponsor
- Georgetown University
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-05-21
- Primary completion
- 2021-11-03
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.